Dose‐finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors

Prexasertib is a novel inhibitor of checkpoint kinase 1. The primary objective of this study was to evaluate prexasertib tolerability in Japanese patients with advanced solid tumors. This nonrandomized single‐arm open‐label phase 1 study of prexasertib consisted of 2 dose levels, 80 mg/m(2) and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasa, Satoru, Yamamoto, Noboru, Shitara, Kohei, Tamura, Kenji, Matsubara, Nobuaki, Tajimi, Masaomi, Lin, Aimee B., Asou, Hiroya, Cai, Zhihong, Inoue, Koichi, Shibasaki, Yuko, Saito, Kanako, Takai, Hiroki, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247064/
https://www.ncbi.nlm.nih.gov/pubmed/30040168
http://dx.doi.org/10.1111/cas.13750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247064/
https://www.ncbi.nlm.nih.gov/pubmed/30040168
http://dx.doi.org/10.1111/cas.13750

Ejemplares similares